Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* 40-75 years of age~* Clinical diagnosis of moderate to severe COPD~* Current/ex-smokers with at least 10 pack-year smoking history~* Post-bronchodilator FEV1 ≥ 30% and ≤ 70% predicted normal values~* Post-bronchodilator FEV1/FVC ratio of ≤ 0.70~* Post-bronchodilator improvement in FEV1 ≥ 12% and ≤ 30%, and a minimum of 100 mL~* Willing and able to remain at the study site for at least 24 hours at each study visit~* Signed written informed consent~Exclusion Criteria:~* Current evidence or recent history of any clinically significant and unstable disease or abnormality (e.g., myocardial infarction, cardiac failure, uncontrolled hypertension, life-threatening arrhythmias, uncontrolled diabetes)~* Primary diagnosis of asthma~* History of malignancy within the past 5 years~* History of COPD exacerbation within 6 weeks of Screening~* Daily oxygen therapy \> 10 hours per day~* Systemic steroids use within 6 weeks of Screening~* Respiratory tract infection within 6 weeks of Screening~* History of tuberculosis, bronchiectasis~* History of urinary retention or bladder neck obstruction type symptoms~* History of glaucoma~* Prolonged QTc interval (\>460msec) or history of long QT syndrome~* Recent history of alcohol or drug abuse~* Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice acceptable birth control methods~* History of hypersensitivity or intolerance to aerosol medications~* Participation in another investigational drug study within 30 days of Screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EP-101 via nebulizer (eFlow®) 25 ug (Type: EXPERIMENTAL): EP-101 via nebulizer (eFlow®)
- Tiotropium bromide via (Spiriva® Handihaler®) (Type: ACTIVE_COMPARATOR): Tiotropium bromide via (Spiriva® Handihaler®)
- Ipratropium bromide Inhalation Solution (Type: ACTIVE_COMPARATOR): Ipratropium bromide Inhalation Solution via Handihaler® DPI
- Placebo EP-101 (Type: PLACEBO_COMPARATOR): Placebo
- EP-101 via nebulizer (eFlow®) 50 ug (Type: EXPERIMENTAL): EP-101 via nebulizer (eFlow®)
- EP-101 via nebulizer (eFlow®) 100 ug (Type: EXPERIMENTAL): EP-101 via nebulizer (eFlow®)
- EP-101 via nebulizer (eFlow®) 200 ug (Type: EXPERIMENTAL): EP-101 via nebulizer (eFlow®)

Based on this trial design, predict the completion outcome and termination type (if applicable).